Calling everyone in Abuja!
A child urgently needs B- or O- blood at Maitama District Hospital. If you are eligible or know someone who is,
please call 08068556713 or 07039163152.
URGENT BLOOD DONATION APPEAL
Please, I need your help. My son is currently at Maitama District Hospital, Abuja, and he urgently needs a blood donor.
His blood group is Bโ (B negative). We need anyone who can donate B negative or O negative blood.
If you are able to donate or know someone who can help, please contact me on:
๐ 08068556713
๐ 07039163152
Please share this post widely. Someoneโs help could make a huge difference for my son.
Meet Gloriaโa talented braider & sickle-cell warrior in Abuja who recently lost both parents. Despite chronic pain & medical bills, she shows up every day. She doesn't need pity, she needs support! ๐
Prof. Mokuolu says
Dear NMA members, this statement from the US CDC is not a global recommendation on using Artemether-Lumefantrine. It is a specific US action in relation to travellers with Malaria who are coming from malaria-endemic regions. It involved a study of 47 US patients with malaria. 40 were treated with Artemether-Lumefantrine, and 7 were treated with Artesunate-Pyronaridine. High levels of treatment failure were reported, and some had severe malaria. The CDC use these findings to recommend extended duration. Malaria behaves differently between non-immune and partially immune populations, which is why most contemporary recommendations are based on studies from different regions of the world before making globally applicable statements. Please note the sample size of an observational series. In the US, they can only rely on these types of series, as they are unlikely to have the numbers for a randomised clinical trial. For the reasons indicated, the authors restricted their recommendation to the US. So, while off-label, the action is also limited to the US setting. Another point is that the report focuses on treatment failures. Treatment failures do not necessarily indicate resistance but can be an important early signal. But in the strict sense, treatment failure is failure to achieve the treatment objective, regardless of the underlying factors. The cited report described treatment failure and found that the factors were multifactorial, as they should be. In Nigeria, the scenario is different; It is a partially immune population. We monitor responses to ACTs through regular therapeutic efficacy studies. Currently, the 2026 study is being conducted in Kwara, Sokoto, Cross River, and an additional state. The Programme covers about 7-8 states to ensure inclusion of each geopolitical zone within a 2-year cycle since 2018. I hope this offers reassurance that we are applying the best available evidence to the treatment guidelines. Typically treatment failure will be documented and that is why a corrected PCR result is conducted to distinguish between recrudescence and reinfection. So far our PCR corrected parasitological cure rate averages 97-99% across different ACTs. That said, we must embrace practices that are geared towards resistance prevention and where there are early signs we adopt resistance mitigation. So like every proactive system, the National Malaria Elimination Programme has just developed an Antimalarial Drug Resistance (AMDR) strategy for the country. It is awaiting Ministerial clearance, and it will go into circulation shortly. Our best practice remains *ensuring parasitological diagnosis before treatment* in all suspected cases of malaria. We need to trust our RDT results and ensure our lab personnel are trained in malaria microscopy. *Continue using the currently recommended ACTs as a 3-day treatment*. We have several chemoprevention strategies, such as Seasonal Malaria Chemoprevention, and starting next year, a malaria vaccine will be deployed in Kwara. *Use AL for pregnant women in the first trimester* if confirmed to have malaria. In other trimesters, other ACTs can be used except Artesunate-Pyronaridine, for which WHO cannot comment due to a lack of data. We are also encouraging the use of various ACTs to increase parasite exposure to multiple molecules, in what is called Multiple First Line Therapies (contained in the AMDR strategy, with Kwara as a pilot State). We are at an advanced stage of examining fixed-dose Triple ACTs, all with a view to proactively having AMDR-related options in place. We are following this path strategically, and it is better to have exposure to multiple molecules than extended use. I recommend we maintain the current AL prescription of 3 days and allow the country to issue guidelines as needed. Before you jump onto the train, remember, the recommendation was not made for here. The questions we have to deal with with every strategy are: are we addressing treatment
Yes we are very egoistic.
You know why.
A couple of weeks ago, I cut up a pregnant woman, met a ruptured uterus, brought out the life baby , repaired the womb, and sewed everything back up neat and nicely.
The second day, she was on her feet walking.
And that's just me, I'm a kid compared to other.
Dr Ose literally puts in probes and rods in people and fixes problems you can't even imagine.
Neurosurgeons can literally cut out the part of the brain that you used to type this tweet.
And yes, they can do it while you're awake.
CT surgeons and interventional cardiologist operate on a heart that is beating. That's like a mechanic working on a car with the engine running.
So yes aunty.
We are very egoistic because when we are not around, people die.
If you're not around, the only thing that happens is reduced revenue.
Do am if e easy.